08:08 AM EDT, 07/02/2025 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Wednesday it completed the sale of its Rare Pediatric Disease Priority Review Voucher on June 27, receiving gross proceeds of $155 million.

The US Food and Drug Administration awarded the voucher in April following approval of zevaskyn, a gene therapy for treating adults and pediatric patients with recessive dystrophic epidermolysis bullosa, Abeona said.

Abeona Chief Financial Officer Joe Vazzano said the company expects to begin the first patient treatment with zevaskyn in Q3, and reach profitability by early 2026.

The biopharmaceutical company said its unaudited cash and equivalents totaled about $225 million as of June 30, including proceeds from the sale.

Shares were 3.2% higher in recent premarket activity.